Published in New England Journal of Medicine.
Showing the critical role of a CCR5 deletion in resistance to HIV1 infection
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Gero Hütter, M.D et al.
N Engl J Med 2009; 360:692-698February 12, 2009
Infection with the human immunodeficiency virus type 1 (HIV-1) requires the presence of a CD4 receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Homozygosity for a 32-bp deletion in the CCR5 allele provides resistance against HIV-1 acquisition.
Popular article covering this:
By Tom Watkins, CNN
December 15, 2010 4:10 a.m. EST
….. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, called it impractical. “It’s hard enough to get a good compatible match for a transplant like this,” he said in a statement. “But you also have to find (a) compatible donor that has this genetic defect, and this defect is only found in 1% of the Caucasian population and 0% of the black population. This is very rare.”…
….. But AIDS researchers predicted the report will have little impact on practice.
“This probably is a cure, but it comes at a bit of a price,”….